Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XLO Stock Forecast 2026-2027
$0.65
Current Price
$43.63M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to XLO Price Targets
+209.6%
To High Target of $2.00
+209.6%
To Median Target of $2.00
+209.6%
To Low Target of $2.00
XLO Price Momentum
-9.7%
1 Week Change
0.0%
1 Month Change
-39.8%
1 Year Change
+1.6%
Year-to-Date Change
-62.0%
From 52W High of $1.70
+5.0%
From 52W Low of $0.62
📊 TOP ANALYST CALLS
Did XLO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Xilio Therapeutics is one of their latest high-conviction picks.
Latest XLO Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, XLO has a bullish consensus with a median price target of $2.00 (ranging from $2.00 to $2.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.65, the median forecast implies a 209.6% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Daina Graybosch at Leerink Partners, projecting a 209.6% upside. Conversely, the most conservative target is provided by Daina Graybosch at Leerink Partners, suggesting a 209.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XLO Analyst Ratings
1
Buy
0
Hold
0
Sell
XLO Price Target Range
Low
$2.00
Average
$2.00
High
$2.00
Current: $0.65
Latest XLO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XLO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 6, 2025 | Leerink Partners | Daina Graybosch | Outperform | Initiates | $2.00 |
| Nov 8, 2024 | Raymond James | Dane Leone | Outperform | Maintains | $4.00 |
| May 30, 2023 | Chardan Capital | Matthew Barcus | Buy | Reiterates | $7.00 |
| May 11, 2023 | Chardan Capital | Matthew Barcus | Buy | Reiterates | $7.00 |
| Jan 27, 2023 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $10.00 |
| Dec 21, 2022 | Chardan Capital | Matthew Barcus | Buy | Initiates | $7.00 |
| Nov 10, 2022 | Raymond James | Dane Leone | Outperform | Maintains | $13.00 |
| Aug 10, 2022 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $20.00 |
| Jan 10, 2022 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Nov 16, 2021 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Nov 16, 2021 | Raymond James | Outperform | Initiates | $N/A | |
| Nov 16, 2021 | Morgan Stanley | Overweight | Initiates | $N/A |
Xilio Therapeutics, Inc. (XLO) Competitors
The following stocks are similar to Xilio Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Xilio Therapeutics, Inc. (XLO) Financial Data
Xilio Therapeutics, Inc. has a market capitalization of $43.63M with a P/E ratio of -0.6x. The company generates $31.80M in trailing twelve-month revenue with a -183.9% profit margin.
Revenue growth is +742.5% quarter-over-quarter, while maintaining an operating margin of -10.1% and return on equity of -908.3%.
Valuation Metrics
Market Cap
$43.63M
Enterprise Value
$-62,071,284
P/E Ratio
-0.6x
PEG Ratio
0.0x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+742.5%
Gross Margin
N/A
Operating Margin
-10.1%
Net Margin
-183.9%
EPS Growth
+742.5%
Financial Health
Cash/Price Ratio
+305.9%
Current Ratio
2.2x
Debt/Equity
-0.9x
ROE
-908.3%
ROA
-26.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Xilio Therapeutics, Inc. (XLO) Business Model
About Xilio Therapeutics, Inc.
What They Do
Develops immuno-oncology therapies for cancer treatment.
Business Model
Xilio Therapeutics Inc. generates revenue through the discovery and development of innovative immuno-oncology therapeutic candidates. By leveraging its proprietary technology platform, the company focuses on creating tumor-activated therapies that enhance drug efficacy while minimizing side effects. Their pipeline includes small molecule therapeutics and bioengineered cytokines targeting various cancer types.
Additional Information
Operating in a specialized and competitive biotech sector, Xilio is positioned as a significant player in cancer treatment advancements. The company aims to transform cancer therapy and improve patient quality of life, making it an attractive prospect for investors interested in healthcare innovation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
64
CEO
Dr. Rene Russo BCPS, Pharm.D.
Country
United States
IPO Year
2021
Website
xiliotx.comXilio Therapeutics, Inc. (XLO) Latest News & Analysis
Latest News
Quick Summary
The company raised $35.8 million from Series B warrant exercises, extending its cash runway into Q2 2027, with participation from Coastlands Capital, Frazier Life Sciences, and Gilead Sciences.
Why It Matters
The $35.8 million raised extends the cash runway, indicating financial stability and potential for growth, which can boost investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
2 months ago
Quick Summary
Xilio Therapeutics reported a 40% objective response rate for vilastobart in MSS mCRC patients. Phase 1 data for efarindodekin alfa showed promising activity. The company expects cash runway into Q1 2027.
Why It Matters
Positive clinical trial results for Xilio Therapeutics’ therapies could boost stock prices, indicating potential revenue growth and market confidence in their innovative cancer treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Xilio Therapeutics (XLO) reported a quarterly loss of $0.03 per share, matching estimates and improving from a loss of $0.22 per share a year earlier.
Why It Matters
Xilio Therapeutics' quarterly loss narrowing indicates improved financial performance, potentially boosting investor confidence and impacting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Xilio Therapeutics discussed Phase 2 data for Vilastobart and the role of high plasma TMB as a predictive biomarker in MSS mCRC during a conference call on November 10, 2025.
Why It Matters
Xilio Therapeutics' Phase 2 data on Vilastobart and its predictive biomarker could influence stock performance, signaling potential advancements in treatment for MSS mCRC and impacting investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Xilio Therapeutics (Nasdaq: XLO) announced promising preclinical and Phase 1/2 data for its immuno-oncology therapies, highlighting strong anti-tumor activity and safety profiles for efarindodekin alfa and vilastobart.
Why It Matters
Xilio's promising data on its immuno-oncology therapies highlights potential for significant advancements in cancer treatment, likely boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A 40% overall response rate (ORR) was observed in heavily pre-treated patients with mismatch repair-stable metastatic colorectal cancer (mCRC) lacking liver metastases and high plasma tumor mutational burden (TMB).
Why It Matters
A 40% overall response rate in difficult-to-treat mCRC patients indicates potential for effective therapies, impacting drug valuations and market dynamics in oncology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About XLO Stock
What is Xilio Therapeutics, Inc.'s (XLO) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Xilio Therapeutics, Inc. (XLO) has a median price target of $2.00. The highest price target is $2.00 and the lowest is $2.00.
Is XLO stock a good investment in 2026?
According to current analyst ratings, XLO has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XLO stock?
Wall Street analysts predict XLO stock could reach $2.00 in the next 12 months. This represents a 209.6% increase from the current price of $0.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xilio Therapeutics, Inc.'s business model?
Xilio Therapeutics Inc. generates revenue through the discovery and development of innovative immuno-oncology therapeutic candidates. By leveraging its proprietary technology platform, the company focuses on creating tumor-activated therapies that enhance drug efficacy while minimizing side effects. Their pipeline includes small molecule therapeutics and bioengineered cytokines targeting various cancer types.
What is the highest forecasted price for XLO Xilio Therapeutics, Inc.?
The highest price target for XLO is $2.00 from Daina Graybosch at Leerink Partners, which represents a 209.6% increase from the current price of $0.65.
What is the lowest forecasted price for XLO Xilio Therapeutics, Inc.?
The lowest price target for XLO is $2.00 from Daina Graybosch at Leerink Partners, which represents a 209.6% increase from the current price of $0.65.
What is the overall XLO consensus from analysts for Xilio Therapeutics, Inc.?
The overall analyst consensus for XLO is bullish. Out of 5 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are XLO stock price projections?
Stock price projections, including those for Xilio Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:56 AM UTC